What is Variantyx?
Variantyx operates at the forefront of molecular diagnostics, specializing in comprehensive whole-genome sequencing. Their service portfolio encompasses a wide array of genetic tests, including targeted and broad analyses, all performed on a proprietary whole genome platform. The company's innovative approach is designed to enhance diagnostic accuracy and efficiency, particularly for complex genetic conditions. By providing state-of-the-art genomic tests and enabling personalized medicine, Variantyx aims to significantly improve patient outcomes and quality of life.
How much funding has Variantyx raised?
Variantyx has raised a total of $130.8M across 7 funding rounds:
Series A
$3M
Series B
$10M
Debt
$350K
Series C
$20M
Other Financing Round
$41.5M
Debt
$20M
Private Equity
$36M
Series A (2017): $3M, investors not publicly disclosed
Series B (2019): $10M led by Pitango Venture Capital and New Era Capital Partners
Debt (2020): $350K supported by PPP
Series C (2021): $20M featuring IBM Ventures, Pitango Venture Capital, New Era Capital Partners, 20/20 HealthCare Partners, and GHS Fund
Other Financing Round (2022): $41.5M backed by Peregrine Ventures, 20/20 HealthCare Partners, Pitango Venture Capital, New Era Capital Partners, and Rbvc
Debt (2022): $20M with participation from Kreos Capital Group
Private Equity (2024): $36M led by New Era Capital Partners and Peregrine Ventures
Key Investors in Variantyx
New Era Capital Partners
New Era Capital Partners is a venture capital and private equity firm that invests in technology and life science innovations. They are known for supporting companies from early stages through maturity, providing strategic guidance and capital to foster growth.
Peregrine Ventures
Peregrine Ventures is a global investment group focused on advancing medical innovation through strategic investments in life science companies. They support portfolio companies from early to mid-stage development, aiming to bring groundbreaking healthcare technologies to market.
Pitango Venture Capital
Pitango Venture Capital is a leading venture capital firm that partners with visionary entrepreneurs and groundbreaking companies. They operate across multiple funds, including HealthTech, and provide value-added support to foster innovation and growth in their portfolio companies.
What's next for Variantyx?
The recent major strategic investment positions Variantyx for an accelerated phase of growth and innovation. This substantial backing is likely to fuel further research and development into advanced sequencing technologies, expand the company's diagnostic offerings, and potentially broaden its market reach. With a clear focus on rare genetic disorders, reproductive genetics, and precision oncology, Variantyx is poised to solidify its role as a key player in the rapidly evolving landscape of genomic diagnostics and personalized healthcare. The company's strategic financing indicates strong investor confidence in its technology and market potential.
See full Variantyx company page
